

Retail Research	IPO Note
Sector: Packaged Food & Nutrition	Price Band (Rs): 42 - 45
03 rd June 2026	Recommendation: SUBSCRIBE for Long Term

Hexagon Nutrition Ltd.

Company Overview:

Hexagon Nutrition Ltd. (HNL) is a global nutrition solutions company engaged in the development and manufacturing of micronutrient premixes, branded clinical nutrition products, and therapeutic nutritional solutions catering to consumers, FMCG players, and international organizations. The company operates in three key segments: (i) premix formulations (B2B2C), (ii) branded nutrition products (B2C), and (iii) therapeutic nutrition solutions including ready-to-use foods (RUFs) and micro nutrient powders (MNPs). HNL has established manufacturing presence across India and international markets, with facilities in Nashik, Chennai, and Thoothukudi, along with an overseas facility in Uzbekistan. HNL caters to a diversified client base including multinational food & beverage companies, dairy players, governments, NGOs, and global health agencies.

Key Highlights:

1. Strong presence in premix formulations segment: Premix formulations remain the core business, contributing 51.5% of revenue in 9MFY26. This segment provides micronutrient premixes used in fortified foods such as dairy products, beverages, and packaged foods, positioning HNL as a key supplier in the nutrition value chain.

2. Diversified business model across B2C and institutional segments: HNL operates a well-diversified model across consumer, corporate, and institutional channels. The B2C segment/therapeutic nutrition (ESG segment) contributed 30.3%/17.9% of revenue in 9MFY26 respectively. This ensures balanced exposure across retail and large-scale institutional demand.

3. Strong export presence and global distribution network: HNL has a well-established international footprint, with exports contributing 55.8% of revenue in 9MFY26. It caters to multiple international markets through a strong distribution network and long-standing relationships with global agencies and corporates, supporting scalable growth across geographies.

Industry Outlook: As per Custom Market Insights and CareEdge Research, the global nutrition market is estimated at USD 731 bn in CY25 and is projected to reach USD 1,239 bn by CY30P, growing at a CAGR of 11.1%. The industry is well-positioned to witness strong growth, supported by rising health awareness and increasing demand for fortified and functional nutrition products.

Key Risks: High dependence on the premix formulations segment (51.5% in 9MFY26), concentration of revenues from a few customers (41.8% - Top 10 customers in 9MFY26), exposure to raw material price volatility, regulatory and compliance risks across food and nutrition categories may pose risks to the company's business performance.

View & Valuation: Hexagon Nutrition Ltd. operates in a structurally growing nutrition and wellness industry, supported by increasing health awareness and rising demand for fortified food products. The company benefits from a diversified business model and holds a strong position in premix formulations, backed by its global presence. The company has demonstrated robust profitability growth, with Revenue, EBITDA, and PAT growing at a CAGR of 8.0%, 35.1%, and 104.6% respectively over FY23–FY25.

At the upper price band of Rs 45, the IPO is valued at a P/E multiple of 15.3x based on annualized 9MFY26 earnings. We recommend investors to SUBSCRIBE to the issue for long-term investment horizon.

Issue Details	
Date of Opening	05 th June 2026
Date of Closing	09 th June 2026
Price Band (Rs)	42 – 45
Offer for Sale (No. of shares)	3,08,59,704 Shares
Total Issue Size (Rs cr)	~139 @ upper band
Total Issue Size (No. of shares)	3,08,59,704 Shares
Face Value (Rs)	1.0
Post Issue Market Cap (Rs cr)	~516 - ~553
BRLMs	Cumulative Capital Pvt. Ltd., Catalyst Capital Partners Pvt. Ltd.
Registrar	KFin Technologies Ltd.
Bid Lot	333 shares and in multiples thereof
QIB shares	50%
Retail shares	35%
NII shares	15%

*The entire issue comprises an Offer for Sale (OFS) and accordingly, the Company will not receive any proceeds from the issue.

Shareholding Pattern		
Pre-Issue	No. of Shares	%
Promoter & Promoter Group	10,98,83,804	89.4
Public & Others	1,30,34,305	10.6
Total	12,29,18,109	100.0

Post Issue @Upper Price Band	No. of Shares	%
Promoter & Promoter Group	7,90,24,100	64.3
Public & Others	4,38,94,009	35.7
Total	12,29,18,109	100.0

Selling shareholders (OFS)	Classification	No. of shares
Arun Purushottam Kelkar	Promoter	15,36,477
Subhash Purushottam Kelkar	Promoter	2,41,88,993
Aditya Kelkar	Promoter	15,26,092
Nutan Subhash Kelkar	Promoter Group	36,08,142
Total	-	3,08,59,704

Source: RHP, SSL Research

Financial Overview

Particulars (Rs cr)	FY23	FY24	FY25	9MFY26	FY23-FY25 CAGR (%)
Revenue	278.5	297.7	324.9	267.6	8.0
YoY (%)	-	6.9	9.1	-	-
EBITDA	22.4	24.5	40.9	37.5	35.1
YoY (%)	-	9.6	66.7	-	-
PAT	5.8	12.2	24.4	27.0	104.6
YoY (%)	-	109.7	99.6	-	-
EBITDA Margin (%)	8.0	8.2	12.6	14.0	-
PAT Margin (%)	2.1	4.1	7.5	10.1	-
ROE (%)	3.6	6.9	12.6	-	-
ROCE (%)	8.4	10.9	17.4	-	-
D/E (x)	0.3	0.2	0.1	0.2	-
P/E (x)	95.0	45.3	22.7	-	-
EV/EBITDA (x)	26.0	23.1	13.7	-	-
CFO	(0.0)	23.4	37.8	(4.1)	-
CFI	(18.7)	3.7	(22.7)	2.0	-
CFF	7.0	(19.1)	(19.2)	10.3	-
FCF	(6.4)	8.4	28.3	(9.8)	-

Source: RHP, SSL Research

Peer Comparison – FY26

Particulars (Rs cr)	Hexagon Nutrition Ltd.*	Zydus Wellness Ltd.	Nestlé India Ltd.
CMP (Rs @ UB)	45	498	1,399
Mkt Cap (@ UB)	553	15,814	2,69,849
Revenue	357	3,961	23,155
EBITDA	50	510	5,306
PAT	36	197	3,545
EBITDA Margin (%)	14.0	12.9	22.9
PAT Margin (%)	10.1	5.0	15.3
RoE (%) - Post issue	15.7	3.4	66.8
P/E (x)	15.3	68.1	78.2
Mkt Cap/Sales (x)	1.6	4.0	11.7

For Hexagon Nutrition Limited the Market cap, P/E(x), and Mkt/Sales (x) are calculated on post-issue equity share capital based on the upper price band.

*The figures presented for Hexagon Nutrition Limited are based on annualized 9MFY26 earnings.

CMP for peer company is closing price as on 02nd June, 2026.

Source: RHP, SSL Research

SBICAP Securities Limited

(CIN): U65999MH2005PLC155485

SEBI Registration No.: Stock Broker: INZ000200032 | DP Registration No.: IN-DP-314-2017

Research Analyst: INH000000602 | IRDA: CA0103 | PFRDA Registration No: POP 26092018

Registered & Corporate Office: Marathon Futurex, Unit No. 1201, B-Wing, 12th Floor, N M Joshi Marg,
Mafatlal Mill Compound, Lower Parel East, Mumbai 400013 .

For any information contact us: **(022) 6854 5555 | E-mail: helpdesk@sbicapsec.com | Web: www.sbisecurities.in**

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. | Research Disclaimer: https://bit.ly/R_disclaimer02 | This is for education/information purposes only. | Trade Name : -SBICAP Securities Limited | SEBI registration Number :- Stock Broker: INZ000200032 | DP Registration No.: IN-DP-314-2017 Research Analyst : INH000000602, IRDAI Corporate Agency Reg. No. CA0103; AMFI Reg. No. ARN-0011; PFRDA Reg. No. POP26092018.

DISCLOSURES & DISCLAIMERS:

Analyst Certification: The views expressed in this research report ("Report") accurately reflect the personal views of the research analysts ("Analysts") employed by SBICAP Securities Limited (SSL) about any and all of the subject issuer(s) or company(ies) or securities. This report has been prepared based upon information available to the public and sources, believed to be reliable. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

The Analysts engaged in preparation of this Report or his/her relative:-

- (a) do not have any financial interests in the subject company mentioned in this Report; (b) do not own 1 or more of the equity securities of the subject company mentioned in the report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the Report.

The Analysts engaged in preparation of this Report:-

- (a) have not received any compensation from the subject company in the past twelve months; (b) have not managed or co-managed public offering of securities for the subject company in the past twelve months; (c) have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (e) has not received any compensation or other benefits from the subject company or third party in connection with the Report; (f) has not served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.

Name	Qualification	Designation
Sudeep Shah	MMS-Finance	VP- Technical & Derivative Research
Sunny Agrawal	B.E, MBA (Finance)	DVP - Fundamental Research
Rajesh Gupta	PGDBM (Finance), MA (Bus. Eco)	AVP - Fundamental Research
Monica Chauhan	C.A.	Research Analyst - Equity Fundamentals
Harsh Vasa	CA	Research Analyst - Equity Fundamentals
Sumeet Shah	B.E., CFA	Research Analyst - Equity Fundamentals
Shubham Purohit	BMS (Finance)	Research Associate - Equity Fundamentals
Vinit Mishra	B.Com	Research Associate - Equity Fundamentals
Avijit Sheet	MBA (Finance)	Research Associate - Equity Fundamentals
Gautam Updhyaya	MBA (Finance)	Research Analyst - Equity Derivatives
Vinayak Gangule	BE (IT)	Research Analyst - Equity Technicals
Ashwin Ramani	B.Com	Research Analyst- Equity Technicals
Sagar Peswani	B.Tech (ECE)	Research Associate - Equity Technicals
Kalpesh Mangade	B.Com	MIS Analyst - Retail Research

For other Disclosures please visit: https://bit.ly/R_disclaimer02

Sudeep Shah
VP – Technical & Derivative Research

Sunny Agrawal
DVP – Fundamental Research